• Home
  •  / Artemis Therapeutics

Artemis Therapeutics

OverviewSuggest Edit

Artemis Therapeutics (formerly known as New York Global Innovations) is a biopharmaceutical company that engages in the development of agents for the prevention and treatment of severe and potentially life-threatening infectious diseases. Its lead drug candidate, Artemisone, is a potent antiparasitic drug for the treatment of malaria.
TypePublic
Founded1997
HQNew York, NY, USMap
Websiteartemis-therapeutics.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2017)1
Revenue (FY, 2014)$244 K(-81%)
Share Price (Jan 2021)$0.2
Cybersecurity ratingAMore

Key People/Management at Artemis Therapeutics

Dana Wolf

Dana Wolf

Chief Medical Officer
Chanan Morris

Chanan Morris

Chief Financial Officer
Show more

Artemis Therapeutics Office Locations

Artemis Therapeutics has offices in New York and San Diego
New York, NY, US (HQ)
18 E 16th St #307
Show all (2)

Artemis Therapeutics Financials and Metrics

Artemis Therapeutics Revenue

Artemis Therapeutics's revenue was reported to be $244 k in FY, 2014
USD

Net income (Q2, 2020)

(6.0k)

EBIT (Q2, 2020)

(57.0k)

Market capitalization (27-Jan-2021)

811.7k

Closing stock price (27-Jan-2021)

0.2

Cash (30-Jun-2020)

3.0k
Artemis Therapeutics's current market capitalization is $811.7 k.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

3.7m1.1m1.3m244.0k

Cost of goods sold

893.0k517.0k564.0k40.0k

Gross profit

2.9m544.0k724.0k204.0k

Gross profit Margin, %

76%51%56%84%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

948.0k1.0m209.0k190.0k516.0k367.0k315.0k300.0k244.0k

Cost of goods sold

223.0k226.0k112.0k124.0k160.0k180.0k112.0k83.0k82.0k

Gross profit

725.0k780.0k97.0k66.0k356.0k187.0k203.0k217.0k162.0k

Gross profit Margin, %

76%78%46%35%69%51%64%72%66%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.4m596.0k334.0k613.0k628.0k907.0k525.0k7.0k2.0k

Accounts Receivable

536.0k145.0k45.0k

Prepaid Expenses

16.0k48.0k

Inventories

407.0k322.0k229.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

2.0m1.1m966.0k454.0k759.0k339.0k314.0k271.0k1.2m748.0k769.0k706.0k655.0k577.0k595.0k1.0m759.0k555.0k345.0k339.0k148.0k38.0k22.0k7.0k3.0k2.0k3.0k

Accounts Receivable

256.0k757.0k36.0k67.0k325.0k303.0k112.0k123.0k59.0k59.0k

Prepaid Expenses

49.0k26.0k11.0k66.0k44.0k44.0k40.0k57.0k49.0k46.0k46.0k40.0k30.0k44.0k33.0k26.0k16.0k31.0k17.0k11.0k60.0k

Inventories

336.0k363.0k431.0k406.0k364.0k315.0k319.0k275.0k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(489.0k)(1.1m)(298.0k)362.0k(139.0k)(264.0k)(1.1m)(513.0k)(121.0k)

Depreciation and Amortization

23.0k25.0k19.0k4.0k

Inventories

(178.0k)85.0k93.0k229.0k

Accounts Payable

74.0k(137.0k)61.0k(140.0k)(5.0k)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(120.0k)(12.0k)(470.0k)(890.0k)(949.0k)(111.0k)(203.0k)(165.0k)673.0k546.0k(33.0k)(105.0k)(123.0k)(40.0k)(58.0k)(18.0k)(185.0k)(421.0k)(648.0k)(211.0k)(352.0k)(460.0k)(21.0k)(90.0k)(114.0k)(21.0k)(27.0k)

Depreciation and Amortization

11.0k17.0k7.0k12.0k19.0k5.0k11.0k15.0k4.0k4.0k

Inventories

(107.0k)(134.0k)(24.0k)1.0k43.0k7.0k3.0k47.0k229.0k229.0k

Accounts Payable

1.0k52.0k(150.0k)(169.0k)(159.0k)55.0k2.0k(47.0k)(6.0k)(141.0k)(5.0k)(5.0k)
show all
USDQ2, 2011

Financial Leverage

1.8 x
Show all financial metrics

Artemis Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

Learn more about our premium products
SecurityScorecard logo

Artemis Therapeutics Online and Social Media Presence

Artemis Therapeutics's Trends

Embed Graph

Artemis Therapeutics News and Updates

June 19, 2018

Artemis Therapeutics Announces Two Recent Publications Highlighting Artemisone's Activity Against Human Cytomegalovirus And Malaria

SAN DIEGO, June 19, 2018 /PRNewswire/ -- Artemis Therapeutics, Inc. (OTCQB: ATMS), ("Artemis" or the "Company"), a pharmaceutical company developing new therapies for the treatment of infectious diseases, including cytomegalovirus and malaria, today announced that data on its lead product...

 Artemis Therapeutics Frequently Asked Questions

  • When was Artemis Therapeutics founded?

    Artemis Therapeutics was founded in 1997.

  • Who are Artemis Therapeutics key executives?

    Artemis Therapeutics's key executives are Dana Wolf and Chanan Morris.

  • How many employees does Artemis Therapeutics have?

    Artemis Therapeutics has 1 employees.

  • Who are Artemis Therapeutics competitors?

    Competitors of Artemis Therapeutics include Biogen, Inovio Pharmaceuticals and MyoKardia.

  • Where is Artemis Therapeutics headquarters?

    Artemis Therapeutics headquarters is located at 18 E 16th St #307, New York.

  • Where are Artemis Therapeutics offices?

    Artemis Therapeutics has offices in New York and San Diego.

  • How many offices does Artemis Therapeutics have?

    Artemis Therapeutics has 2 offices.